Delving into the Latest Updates on Respiratory Syncytial Virus Vaccine (Xiamen Innovax) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Genetically engineered subunit vaccine

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious Diseases

Active Indication

Respiratory Syncytial Virus Infections

Inactive Indication-

Originator Organization

Xiamen Innovax Biotech Co., Ltd.

Active Organization

Xiamen Innovax Biotech Co., Ltd.

Chengdu Maxvax Biotechnology LLC

Xiamen University

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

评价重组呼吸道合胞病毒疫苗（CHO细胞）在单剂接种后，预防60周岁及以上人群中经逆转录-聚合酶链式反应（RT-PCR）确认因呼吸道合胞病毒亚型A（RSV-A）和/或亚型B（RSV-B）感染引起的下呼吸道疾病（LRTD）的有效性。同时，评价疫苗接种的安全性和免疫原性。

[Translation]

To evaluate the effectiveness of a recombinant respiratory syncytial virus vaccine (CHO cells) in preventing lower respiratory tract disease (LRTD) caused by respiratory syncytial virus subtype A (RSV-A) and/or subtype B (RSV-B) infection, as confirmed by reverse transcription-polymerase chain reaction (RT-PCR), in people aged 60 years and older after a single dose. The safety and immunogenicity of the vaccine were also evaluated.

Start Date22 Oct 2025

Sponsor / Collaborator

Shanghai Maikekang Biotechnology Co., Ltd.

[+1]

NCT07272434

/ RecruitingPhase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 60 Aears and Above

This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.

Start Date22 Oct 2025

Sponsor / Collaborator

Chengdu Maxvax Biotechnology LLC

[+4]

ChiCTR2500110612

/ Not yet recruitingPhase 3

A multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy, immunogenicity, and safety of a recombinant respiratory syncytial virus vaccine (CHO cells) in adults aged 60 years and above

Start Date20 Oct 2025

Sponsor / Collaborator

Shanghai Maikekang Biotechnology Co., Ltd.

[+3]

100 Clinical Results associated with Respiratory Syncytial Virus Vaccine (Xiamen Innovax)

Login to view more data

100 Translational Medicine associated with Respiratory Syncytial Virus Vaccine (Xiamen Innovax)

Login to view more data

100 Patents (Medical) associated with Respiratory Syncytial Virus Vaccine (Xiamen Innovax)

Login to view more data

100 Deals associated with Respiratory Syncytial Virus Vaccine (Xiamen Innovax)

Login to view more data